Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 23304 | 12.98 |
09:34 ET | 2456 | 13.01 |
09:36 ET | 11470 | 12.835 |
09:38 ET | 9929 | 12.71 |
09:39 ET | 1548 | 12.62 |
09:41 ET | 1400 | 12.81 |
09:43 ET | 12318 | 12.79 |
09:45 ET | 872 | 12.7 |
09:48 ET | 1435 | 12.82 |
09:50 ET | 1850 | 12.77 |
09:52 ET | 550 | 12.7887 |
09:54 ET | 200 | 12.81 |
09:56 ET | 1510 | 12.72 |
09:57 ET | 1550 | 12.69 |
09:59 ET | 7800 | 12.55 |
10:01 ET | 100 | 12.53 |
10:03 ET | 1000 | 12.57 |
10:06 ET | 500 | 12.61 |
10:08 ET | 100 | 12.58 |
10:10 ET | 400 | 12.6 |
10:12 ET | 3542 | 12.5825 |
10:14 ET | 2067 | 12.75 |
10:15 ET | 17753 | 12.8227 |
10:17 ET | 900 | 12.86 |
10:19 ET | 2150 | 12.835 |
10:21 ET | 3316 | 12.84 |
10:24 ET | 9111 | 12.79 |
10:26 ET | 7703 | 12.91 |
10:28 ET | 14581 | 12.98 |
10:30 ET | 2747 | 12.975 |
10:32 ET | 6768 | 13 |
10:33 ET | 1204 | 13 |
10:35 ET | 4743 | 13 |
10:37 ET | 9524 | 12.965 |
10:39 ET | 8338 | 12.93 |
10:42 ET | 400 | 12.92 |
10:44 ET | 5712 | 12.93 |
10:46 ET | 29070 | 12.82 |
10:48 ET | 3070 | 12.915 |
10:50 ET | 2900 | 12.92 |
10:51 ET | 100 | 12.92 |
10:53 ET | 790 | 12.93 |
10:55 ET | 1558 | 12.97 |
10:57 ET | 1446 | 12.94 |
11:00 ET | 3756 | 12.91 |
11:02 ET | 5462 | 12.96 |
11:04 ET | 4826 | 12.93 |
11:06 ET | 254 | 12.91 |
11:08 ET | 3410 | 12.82 |
11:09 ET | 1100 | 12.82 |
11:11 ET | 2900 | 12.6954 |
11:13 ET | 1196 | 12.745 |
11:15 ET | 14032 | 12.8 |
11:18 ET | 1300 | 12.805 |
11:20 ET | 800 | 12.82 |
11:22 ET | 3585 | 12.81 |
11:24 ET | 4000 | 12.825 |
11:26 ET | 500 | 12.83 |
11:27 ET | 1539 | 12.88 |
11:29 ET | 13757 | 12.9 |
11:31 ET | 3322 | 12.925 |
11:33 ET | 1300 | 12.95 |
11:36 ET | 45356 | 13.1 |
11:38 ET | 4428 | 13.15 |
11:40 ET | 503 | 13.07 |
11:42 ET | 204 | 13.08 |
11:44 ET | 100 | 13.09 |
11:47 ET | 2800 | 13.03 |
11:49 ET | 486 | 13 |
11:51 ET | 2651 | 13.085 |
11:54 ET | 200 | 13.11 |
11:56 ET | 3059 | 13.08 |
11:58 ET | 848 | 13.08 |
12:00 ET | 200 | 13.05 |
12:02 ET | 600 | 13.05 |
12:03 ET | 1429 | 13.05 |
12:05 ET | 200 | 13.03 |
12:07 ET | 200 | 13.03 |
12:09 ET | 400 | 13.03 |
12:14 ET | 1010 | 13.04 |
12:16 ET | 200 | 13.035 |
12:18 ET | 300 | 13.02 |
12:20 ET | 5364 | 13.115 |
12:21 ET | 1078 | 13.13 |
12:23 ET | 650 | 13.15 |
12:25 ET | 1388 | 13.1013 |
12:27 ET | 400 | 13.14 |
12:30 ET | 4450 | 13.12 |
12:32 ET | 1150 | 13.055 |
12:34 ET | 1300 | 13.03 |
12:36 ET | 200 | 13.035 |
12:39 ET | 500 | 13.03 |
12:41 ET | 1268 | 13.1 |
12:43 ET | 1083 | 13.13 |
12:45 ET | 1899 | 13.15 |
12:48 ET | 202 | 13.12 |
12:50 ET | 200 | 13.13 |
12:52 ET | 823 | 13.13 |
12:54 ET | 22101 | 13.2 |
12:56 ET | 4161 | 13.19 |
12:57 ET | 8260 | 13.14 |
12:59 ET | 1250 | 13.13 |
01:01 ET | 500 | 13.16 |
01:03 ET | 100 | 13.13 |
01:06 ET | 200 | 13.11 |
01:08 ET | 200 | 13.12 |
01:10 ET | 3301 | 13.18 |
01:12 ET | 100 | 13.17 |
01:14 ET | 1260 | 13.19 |
01:15 ET | 700 | 13.18 |
01:17 ET | 218 | 13.18 |
01:19 ET | 15385 | 13.225 |
01:24 ET | 3291 | 13.22 |
01:26 ET | 2400 | 13.25 |
01:28 ET | 2500 | 13.27 |
01:30 ET | 936 | 13.21 |
01:32 ET | 1936 | 13.19 |
01:33 ET | 100 | 13.15 |
01:35 ET | 600 | 13.1899 |
01:39 ET | 300 | 13.15 |
01:42 ET | 1300 | 13.15 |
01:44 ET | 600 | 13.13 |
01:46 ET | 100 | 13.17 |
01:48 ET | 800 | 13.1345 |
01:50 ET | 3131 | 13.175 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 444.6M | -3.7x | --- |
Annexon Inc | 439.3M | -3.1x | --- |
PepGen Inc | 453.1M | -4.2x | --- |
Corbus Pharmaceuticals Holdings Inc | 459.4M | -6.3x | --- |
Lexeo Therapeutics Inc | 460.2M | -5.2x | --- |
Nkarta Inc | 461.6M | -3.0x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $444.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -3.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.